» Articles » PMID: 31788121

Expression and Role of HEPIS in Breast Cancer

Overview
Journal Oncol Lett
Specialty Oncology
Date 2019 Dec 3
PMID 31788121
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Human embryo lung cellular protein interacting with severe acute respiratory syndrome-coronavirus nonstructural protein-10 (HEPIS) is expressed at varying levels in multiple organs and breast cancer cell lines. However, its expression and function in breast cancer cells has yet to be studied. Therefore, RNA hybridization was used to detect the expression of in breast cancer and cancer-adjacent normal breast tissue. was expressed at lower levels in breast cancer compared with that in adjacent normal tissue. Subcellular localization of HEPIS was mainly found in the cytoplasm of HeLa cells. Cell Counting Kit-8 and 5-ethynyl-2'-deoxyuridine cell proliferation assays were used to investigate the role of in cancer cell proliferation. Ectopic expression of HEPIS in MCF-7 cells was found to significantly inhibit cell proliferation. In contrast, knockdown of HEPIS by RNA interference exhibited the opposite effect. Furthermore, a dual-luciferase reporter assay was performed and overexpression specifically inhibited the activity of the NF-κB reporter gene. Results of the gene chip assay revealed that 2,231 genes were differentially expressed in -overexpressing cells. Results of the Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses indicated that these genes were enriched in the 'mitogen-activated protein kinase signaling pathway', 'JAK-STAT signaling pathway' and 'focal adhesion'. Reverse transcription-quantitative PCR was used to confirm the expression levels of the differentially expressed genes interleukin 2 receptor subunit α (), interferon α and β receptor subunit 2 () and IFα8 (). In conclusion, the results of the present study indicated that HEPIS may function as a potential repressor of breast cancer.

Citing Articles

Maslinic acid induces autophagy and ferroptosis via transcriptomic and metabolomic reprogramming in prostate cancer cells.

Hu F, Sun Y, Zhang Y, Chen J, Deng Y, Li Y Front Pharmacol. 2024; 15:1453447.

PMID: 39624845 PMC: 11608986. DOI: 10.3389/fphar.2024.1453447.


PolyI:C attenuates transforming growth factor-β signaling to induce cytostasis of surrounding cells by secreted factors in triple-negative breast cancer.

Tamura Y, Tsutsumi S, Miyazono K, Koinuma D Cancer Sci. 2021; 113(3):940-949.

PMID: 34897916 PMC: 8898727. DOI: 10.1111/cas.15241.


miR‑28‑5p inhibits the migration of breast cancer by regulating WSB2.

Ma L, Zhang Y, Hu F Int J Mol Med. 2020; 46(4):1562-1570.

PMID: 32945370 PMC: 7447326. DOI: 10.3892/ijmm.2020.4685.

References
1.
Sawicki S, Sawicki D, Younker D, Meyer Y, Thiel V, Stokes H . Functional and genetic analysis of coronavirus replicase-transcriptase proteins. PLoS Pathog. 2005; 1(4):e39. PMC: 1298938. DOI: 10.1371/journal.ppat.0010039. View

2.
OShea J, Gadina M, Schreiber R . Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell. 2002; 109 Suppl:S121-31. DOI: 10.1016/s0092-8674(02)00701-8. View

3.
Hu F, Zhang Y . Expression profile and promoter analysis of HEPIS. Exp Ther Med. 2018; 15(1):569-575. PMC: 5763650. DOI: 10.3892/etm.2017.5374. View

4.
Braun S, Harbeck N . Molecular markers of metastasis in breast cancer: current understanding and prospects for novel diagnosis and prevention. Expert Rev Mol Med. 2003; 3(22):1-14. DOI: 10.1017/S1462399401003520. View

5.
Schreiber G, Piehler J . The molecular basis for functional plasticity in type I interferon signaling. Trends Immunol. 2015; 36(3):139-49. DOI: 10.1016/j.it.2015.01.002. View